Biocryst Pharmaceuticals (BCRX) EBT (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) posted EBT of -$720.8 million for Q1 2026, down 390.63% on a QoQ basis from $248.0 million in Q4 2025, and down 95193.4% year-over-year from N/an in Q1 2025.
Biocryst Pharmaceuticals (BCRX) EBT (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' EBT history runs 17 years deep, the most recent figure standing at -$720.8 million for Q1 2026.
- Quarterly EBT fell 95193.4% year-over-year to -$720.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$454.2 million (down 787.37% YoY) and the FY2025 annual result came in at $267.4 million, up 407.51% from the prior year.
- EBT was -$720.8 million for Q1 2026 at Biocryst Pharmaceuticals, down from $248.0 million in the prior quarter.
- Across five years, EBT topped out at $248.0 million in Q4 2025 and bottomed at -$720.8 million in Q1 2026.
- A 5-year average of -$59.5 million and a median of -$35.8 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2025 — EBT surged 1054.24% — and 2026, when it sank 95193.4%.
- Biocryst Pharmaceuticals' EBT stood at -$71.5 million in 2022, then rose by 11.62% to -$63.2 million in 2023, then soared by 58.85% to -$26.0 million in 2024, then jumped by 1054.24% to $248.0 million in 2025, then tumbled by 390.63% to -$720.8 million in 2026.
- Business Quant data shows BCRX's EBT at -$720.8 million in Q1 2026, $248.0 million in Q4 2025, and $12.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 437.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 758.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.90 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 318.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -247.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 246.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 87.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -720.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -720.81 Mn |
| Dec 31, 2025 | 248.02 Mn |
| Sep 30, 2025 | 12.13 Mn |
| Jun 30, 2025 | 6.49 Mn |
| Mar 31, 2025 | 758,000.00 |
| Dec 31, 2024 | -25.99 Mn |
| Sep 30, 2024 | -13.45 Mn |
| Jun 30, 2024 | -12.50 Mn |
| Mar 31, 2024 | -35.01 Mn |
| Dec 31, 2023 | -63.16 Mn |
| Sep 30, 2023 | -35.82 Mn |
| Jun 30, 2023 | -74.59 Mn |
| Mar 31, 2023 | -52.66 Mn |
| Dec 31, 2022 | -71.47 Mn |
| Sep 30, 2022 | -41.00 Mn |
| Jun 30, 2022 | -58.00 Mn |
| Mar 31, 2022 | -73.92 Mn |
| Dec 31, 2021 | -15.53 Mn |
| Sep 30, 2021 | -58.80 Mn |
| Jun 30, 2021 | -43.20 Mn |